Determination of the Absolute Configurations of Chiral Drugs Using Chiroptical Spectroscopy

Prasad L. Polavarapu

Abstract: Chiroptical spectroscopy has emerged as a promising tool for the determination of absolute configurations and predominant conformations of chiral molecules in academic laboratories. This promise has led to the adaption of chiroptical spectroscopic methods as valuable tools in chiral drug discovery research programs of the pharmaceutical industry. Most major pharmaceutical companies have invested in in-house chiroptical spectroscopy applications and reported successful outcomes. In the context of continuously increasing applications of chiroptical spectroscopy for chiral molecular structure determination, a review of recent developments and applications for chiral drugs is presented in this manuscript.

Keywords: chiral; spectroscopy; drugs; electronic circular dichroism; optical rotation; vibrational circular dichroism; vibrational Raman optical activity; absolute configuration; conformation

1. Introduction

Life on planet Earth owes its existence to chirality or handedness. Chiral molecules are those that possess handedness, i.e., in simple terms, they are either left handed or right handed. Only one type of handedness is preferred by the biological molecules that control the life machinery. L-amino acids and D-sugars, are the chiral constituents of proteins and nucleic acids that make up biological systems. As a consequence of the preferential dominance of chirality, drugs that are developed for the treatment of human diseases or upkeep of human health, have to possess the correct handedness. Determination of the handedness of chiral molecules, also referred to as the determination of absolute configuration (AC), has become an important research area. Chiroptical Spectroscopy [1,2] is becoming an invaluable tool for this purpose.

Historically the AC determination was accomplished using X-ray crystallography, nuclear magnetic resonance (NMR) or stereoselective synthetic schemes. These three methods require, respectively, good quality crystals, diastereomeric complexes and labor-intensive chemical synthetic procedures. These disadvantages are avoided in chiroptical spectroscopic applications, where investigations on native samples in solution phase (or vapor phase in favorable situations) can be directly undertaken.

Optical rotation (OR) in the visible spectral region is one chiroptical property that elicited interest in the early days [3]. When normalized with concentration (in g·cc⁻¹) and pathlength (in dm), the resulting quantity is referred to as Specific rotation (SR), or specific optical rotation (SOR) as it is called in the recent literature. SOR is normally considered to be a molecular property that is independent of concentration, although exceptions are known [4]. In the older literature, attempts were made to correlate SOR with AC, mostly via empirical models, but they did not survive the test of time. Circular dichroism (CD) associated with electronic transitions, referred to as electronic CD (ECD), is another chiroptical property that was popularized among synthetic organic chemists by Nakanishi, Harada, Berova, and their coworkers, via the use of an exciton chirality model [5,6].
is limited to molecules that possess two interacting electronic chromophores that absorb light in the
visible spectral regions. A large array of chiral molecules, that do not contain electronic chromophores
absorbing visible light, cannot be studied using this method. This limitation was overcome by the
development of two new methods that measure optical activity associated with vibrational transitions,
which do not depend on the absence or presence of electronic chromophores. One method utilizes the
CD associated vibrational transitions, referred to as vibrational CD (VCD) [7] and the other utilizes the
differential vibrational Raman scattering referred to as vibrational Raman optical activity (VROA) [8,9].
These two vibrational transition-based methods are applicable for all chiral molecules. The four
methods, namely, SOR, ECD, VCD and VROA, are collectively categorized as chiroptical spectroscopic
methods. The advances in chiroptical spectroscopic instrumentation and the availability of commercial
instruments allowed many new researchers to undertake these measurements.

The experimental data obtained with any or all four of the chiroptical methods mentioned in
the previous paragraph, however, cannot by themselves directly reveal the ACs of chiral molecules.
These experimental data must be analyzed with theoretical predictions of corresponding chiroptical
properties to infer the ACs.

The theoretical methods used for predicting chiroptical properties can range from approximate
models to semi empirical methods and to modern quantum chemical (QC) methods. The predictions
resulting from approximate models and semi empirical methods are not reliable enough for
determining the ACs. Due to the revolutionary developments that took place in QC theories [10–12],
thetical predictions resulting from the QC calculations are providing high enough confidence to
reliably analyze the experimental data. The availability of software to undertake the QC calculations,
and of fast computer processors to expedite the calculations has made the applications of chiroptical
spectroscopic methods routine in recent years.

The current practice of determining the ACs of chiral molecules involves experimental
measurement of chiroptical properties for the chemical substance of interest and undertaking QC
calculations for possible structures of the molecules making up that substance. These two steps are
followed by comparative analysis of the experimental and predicted chiroptical spectra.

2. Chiroptical Spectroscopic Tools

In three of the following sub-sections, the instrumentation needed for experimental measurements
and software used for QC predictions and spectral comparison analysis are summarized, to
facilitate the introduction to newcomers. The fourth subsection illustrates a detailed procedure
for AC determination.

2.1. Instrumentation

The instrumentation for optical rotation measurements for liquid samples is well established
and commercial instruments are available (from Jasco Inc., Easton, MD, USA and Rudolph Research
Analytical Inc., Hacketstown, NJ, USA). These instruments, which cost under $20,000, provide
a measurement accuracy of 2 mdeg which is sufficient for most typical cases. Commercial laser
polarimeters (from PDR Chiral Inc., Lake Park, FL, USA), which cost about $40,000, provide a
measurement accuracy of 20 µdeg, and are mostly used with chromatography applications. Optical
rotation measurements for gas phase samples can be undertaken using specialized instruments that
use cavity ring down methods [13–15]. However, these instruments are quite expensive and are
currently limited to academic laboratories. The instrumentation for ECD measurements for liquid
samples is well established and commercial instruments are available (from Jasco Inc., Olis Inc., Bogart,
GA, USA; Applied Photophyscis Inc., Leatherhead, Surrey, UK). These instruments cost ~$150,000.
The instrumentation for VCD measurements for liquid samples is well established and commercial
instruments (from Jasco Inc., Bruker Inc., Billerica MA, USA; BioTools Inc., Jupiter, FL, USA) cost under
~$200,000. The instrumentation for VROA measurements for liquid samples is also well established
and currently there is only one commercial instrument (from BioTools Inc.), which costs ~$275,000.
2.2. QC Software

QC calculations of chiroptical properties can be undertaken on a variety of computer platforms, ranging from desktop computers to supercomputing clusters, using commercially available as well as freeware software. Freeware packages include DALTON [16], Psi4 [17] and NWChem [18], while popular commercial software packages include Gaussian [19] and ADF [20].

2.3. Spectral Comparison Software

Spectral comparison involves comparing the digital experimental spectra with corresponding predicted spectra using spectral overlap integral methods [21,22]. A general purpose freeware program, CDSpecTech, has been developed in the author’s laboratory, to analyze the ECD, VCD and/or VROA spectra, corresponding absorption/Raman spectra and also their ratio spectra [23]. SpecDis, a program restricted to the analysis of ECD and corresponding absorption spectra, is also a freeware program [24]. CompareVOA (from BioTools Inc.) is a commercial program for analyzing the VCD and corresponding absorption spectra [25].

2.4. A Step-by-Step Guide for AC Determination

Centratherin (see Figure 1), a natural product with anti-inflammatory and anti-microbial properties, will be used in this article as an example to lead the reader through different steps involved in the AC determination [26].

![Figure 1. The (6R,7R,8S,10R,2′Z) structure of centratherin [26].](image)

The experimental chiroptical spectral data are obtained for the sample of interest dissolved in an appropriate solvent. If the solvent used does not participate in solute-solvent intermolecular hydrogen bonds, then corresponding QC calculations can be handled, relatively easily, with implicit solvation models. If intermolecular hydrogen bonding between solvent and solute is involved, then corresponding QC calculations need to incorporate explicit solvent molecules to effectively incorporate solvent effects into the calculations. The use of solvents that do not participate in intermolecular hydrogen bonding are to be favored, unless the goal is to unravel the intermolecular hydrogen bonding itself. Nevertheless, experimental measurements in different solvents at different concentrations are useful to assess the influence of solvents and concentrations.

The experimental ECD and VCD spectra and corresponding absorption spectra for centratherin measured in acetonitrile solvent [26] are shown in Figures 2 and 3, respectively. The experimental ROA spectra could not be measured for centratherin due to fluorescence issues and lack of the availability of enough sample. The experimentally measured SOR for centratherin [26] at 589 nm is
−12 deg·cc·g⁻¹·dm⁻¹. Since the sample used for experimental measurements has negative SOR at 589 nm, this sample will be labeled as (−)589-centratherin.

**Figure 2.** (A) Experimental and predicted electronic absorption spectra. Inset shows the similarity overlap plot as a function of wavelength scale factor; (B) experimental and predicted ECD spectra. Inset shows the similarity overlap plot as a function of wavelength scale factor; (C) experimental and predicted EDF spectra. Inset shows the similarity overlap plot as a function of wavelength scale factor. The experimental spectra are for (−)589-centratherin and predicted spectra are for (6R,7R,8S,10R,2'Z) structure. Data taken from Reference [26].
Figure 3. (A) Experimental and predicted vibrational absorption spectra. Inset shows the similarity overlap plot as a function of wavenumber scale factor; (B) experimental and predicted VCD spectra. Inset shows the similarity overlap plot as a function of wavenumber scale factor; (C) experimental and predicted VDF spectra. Inset shows the similarity overlap plot as a function of wavenumber scale factor. The experimental spectra are for (−)589-centratherin and predicted spectra are for (6\text{R},7\text{R},8\text{S},10\text{R},2'\text{Z}) structure. Data taken from Reference [26].
Once a reliable set of experimental data has been gathered, QC calculations of chiroptical properties are initiated. The basic requirement for theoretical predictions of chiroptical properties is that the correct chemical structure of the compound of interest is known. Here chemical structure is meant to represent the chemical composition (atomic constituents) and the atomic connectivities (which atom is connected to which). Given that information, the three dimensional arrangement of atoms in a chiral molecule is the question that will be addressed by chiroptical spectroscopy. The three dimensional arrangement of atoms in a chiral molecule is defined by the ACs at individual chiral centers and dihedral conformations. Quite often, the relative ACs of the chiral centers may have been determined in the literature. If relative ACs are known with definite certainty, then theoretical predictions can be undertaken for that one diasteromer and conformational analysis conducted to predict the chiroptical properties. For situations where there is no prior information on the ACs of individual chiral centers, one would need to consider all possible diastereomers (and dihedral conformations associated with each diastereomer) and predict the chiroptical properties for all those possibilities. For a compound possessing “n” sources of chirality there will be $2^n$ diasteromers. Here, a source represents many of the types of chirality (for example, central chirality, axial chirality, etc.). One needs to consider $2^n - 1$ diastereomers for theoretical predictions, because one-half of the $2^n$ diastereomeric structures are mirror images of the other half and their chiroptical properties would be opposite of the other half. For compounds possessing multiple sources of chirality, this situation can turn into a computational nightmare. More often than not, ACs for some of the chiral centers may have already been determined by other means (such as NOEs from NMR spectra), which will permit fixing the ACs at certain centers in the molecule, thereby reducing the computational demand.

The relative AC of centratherin (see Figure 1) is known from the literature as $(6R,7R,8S,10R,2'Z)$, and therefore this diastereomer was used for the theoretical calculations [26].

The first step in the process for theoretical predictions is to build a molecular model. This involves pre-defining the chirality at individual chiral centers (and axial chirality, if one is involved) of the molecule of interest. There are several molecular visualization programs that can be used to build the molecular models. A popular freeware program is Avogadro [27]. Then a conformational search is carried out for the starting structure. A variety of commercial conformational search programs (Spartan [28], Conflex [29], Hyperchem [30], Macromodel [31]) are available for this purpose. It is important to make sure that all of the conformations found belong to the same diastereomer. If some conformers are found to have altered ACs then they need to be appropriately modified before further processing. The conformations determined with conformational search programs, within 20 kcal/mol of energy, need to be further refined using QC programs via geometry optimization options. A good compromise for the QC level of theory to be used here is B3LYP functional and 6-31G* basis set. The energies of optimized geometries at this level are compared and the lowest energy conformers within a certain energy range are retained for further geometry optimization at a higher level of theory. It is important to verify that the optimized conformers are at the minimum of potential energy, by performing vibrational frequency calculations and ensuring that there are no imaginary vibrational frequencies.

For the $(6R,7R,8S,10R,2'Z)$ structure, sixteen lowest energy conformations, within 3 kcal/mol range at B3LYP/6-31G* level were reoptimized at B3LYP/aug-cc-pVDZ level of theory [26].

Then, chiroptical properties are calculated for all of these selected conformers with one particular AC. For the OR phenomenon, the predicted chiroptical property is the SOR at specific wavelengths. The chiroptical properties predicted for the CD phenomenon are the rotational strengths for each of the transitions. For the corresponding absorption phenomenon, the predicted properties are dipole strengths for each of the transitions. For the ROA phenomena, the properties predicted include normal coordinate derivatives of three different polarizability tensors (namely, electric dipole-electric dipole (EDED), electric dipole-magnetic dipole (EDMD) and electric dipole-electric quadrupole (EDEQ)) for each of the vibrational transitions. The anisotropies of these tensors are combined in an appropriate
form to derive the activity associated with the ROA phenomena \[9,32,33\]. The anisotropy of EDED polarizability derivative tensor determines the activity associated with Raman spectra.

Rotational strengths in the case of CD phenomenon, and activities in the case of ROA phenomenon, are merely the signed numbers that represent integrated band intensities in the CD or ROA spectra. Dipole strengths in the case of absorption associated with CD, or Raman activities in the case of Raman associated with ROA, are positive numbers that represent integrated absorption band intensities in absorption or Raman spectra. They all can only be compared with corresponding integrated band intensities in the experimentally measured spectra. The task of integrating the band areas in the experimentally measured spectra is laborious, and may not provide easy comparison to the predicted quantities when multiple transitions overlap. Therefore, the opposite procedure is used by converting the predicted integrated band intensities into simulated predicted spectra, which can be compared with experimentally observed spectra. Simulation of theoretical spectra involves the assumptions of a band profile (Gaussian, Lorentzian, etc.) and a bandwidth for each of the transitions. For convenience, all transitions are assumed to have the same band profile and one chosen bandwidth. All these simulations can be conveniently undertaken using the spectral comparison software \[23\]. Since SOR is a cumulative effect from all electronic transitions, there is no simulation involved for theoretical SOR predictions.

For the \((6^R,7^R,8^S,10^R,2^Z)\) structure, sixteen lowest optimized energy conformations were used for ECD and ORD calculations at CAM-B3LYP/aug-cc-pVDZ level and for VCD at B3LYP/aug-cc-pVDZ level of theory.

The calculated chiroptical properties for individual conformers (all with the same predefined AC) are to be weighted with their percent populations, referred to as Boltzmann populations or weights. These Boltzmann weights can be determined from the electronic energies or Gibbs energies obtained in the QC calculations. The Boltzmann weighted predicted ECD and VCD spectra for \((6^R,7^R,8^S,10^R,2^Z)\) diastereomer are shown in Figures 2B and 3B, while the corresponding absorption spectra are shown in Figures 2A and 3A. The predicted population weighted SOR, for \((6^R,7^R,8^S,10^R,2^Z)\) structure, is \(-44 \text{ deg}\cdot\text{cc}\cdot\text{g}^{-1} \cdot \text{dm}^{-1}\) at 589 nm.

**Visual analysis of chiroptical spectra:** At the simplest level of spectral comparison analysis, the experimental and predicted chiroptical spectra are visually compared to assess the agreement between them. To facilitate the visual comparison, lines are drawn correlating the bands observed in the experimental spectra with those in the calculated spectra. In the case of ORD, SOR values measured at discrete wavelengths are compared to those obtained in the calculations (keeping in mind that the calculated wavelengths may have been shifted from the experimental wavelengths). From Figures 2 and 3, it can be seen that the experimental data for the enantiomer with negative SOR at 589 nm matches that predicted for \((6^R,7^R,8^S,10^R,2^Z)\) diastereomer. Therefore, the AC of centratherin can be assigned \[26\] as \((-)_{589}(6^R,7^R,8^S,10^R,2^Z)\).

Most of the reported chiroptical spectral analyses for chiral drugs were accomplished via visual spectral analyses. A table summarizing the chiral drugs whose ACs were investigated \[34–90\] using chiroptical spectroscopic methods are summarized in Table 1. Occasional reviews have also highlighted some of these chiral drugs \[42,65,91,92\]. There are several natural products with promising medicinal values where ACs were investigated using chiroptical spectroscopy, but it will be unwieldy to review all of them here.
Table 1. Chiral molecules with pharmaceutical applications investigated for their absolute configurations.

| Molecule | Methods Used | Practical Use | References |
|----------|--------------|---------------|------------|
| (15,2S,3R)-1-acetoxyisomethyl-2,3,4,4-tetra-methylcyclopentane | VCD | pheromone | [34] |
| Aeroplysinin-1 | VCD, ROA | treatment of antiangiogenic disease | [35] |
| (S)-alapride | ECD, ORD | veterinary ointment | [36] |
| (S)-altamarkam | VCD | fungal cytotoxic | [37] |
| (S)-AM3189 | VCD, OR | diabetes treatment | [38] |
| (15,4S)-amino-aza-benzimidazolone | VCD | positive allosteric modulators | [39] |
| (P)-4-amino-2-cyclopropyl-5-(2-fluoro-6-methoxyphenyl)-2,3-dihydro-pyrrolo[3,4-b]quinolin-1-one | VCD | atropisomers of GABA modulator | [40] |
| (S,R,R)-Apalpit | VCD | neurokinin 1 (NK1) receptor antagonist | [41] |
| (1R,5S)-1-azabicyclo[3.1.0]hexane | VCD | principle structural fragment of antitumor antibiotics azinomycins A and B | [42] |
| (S)-AZD624 | VCD | NK3 antagonist | [43] |
| (S)-AZD6765 | ECD | NMDA antagonist | [44] |
| (R,S) and (S,S)-Bedaquiline Analogs | VCD | Active component of vasopressin receptor antagonist | [45] |
| (S)-benzodiazipine | VCD | Calcium Channel antagonist | [46] |
| (S) and (R)-2-(3,3-bis(trifluoromethyl)phenyl)-N-(4-(2-methylpyridin-4-yl)phenyl)propanamide | VCD | synthesis of Glucokinase regulatory protein disruptor | [47,48] |
| (2S,3R,6S)-2-Benzyl-5,6-bis(4-bromophenyl)-4-methylmor-pholin-3-one | VCD, OR | synthesis of Glucokinase regulatory protein disruptor | [49] |
| (R)-8-(4-bromophenyl)-8-ethoxy-8-H-[1,2,4]oxadiazol-3-one | VCD, OR, VCD | Calcium Channel antagonist | [50] |
| (S) and (R)-4-bromophenyl[(iminio)trifluoromethyl]]-N,s-sulfanone | VCD | antinflammatory | [51] |
| (S) and (R)-(4-bromophenyl)-[alpha](trifluoromethyl) N,s-sulfolane | ECD | MDM2-p53 inhibitor | [52] |
| (8R,7S)-chomedotriazolopyrimidin | VCD | functionality that can yield intermediates for the synthesis of chiral drugs | [53] |
| (2R,3R) and (2S,3S)-2-chlorophenylglycidol | VCD, OR, ECD | function that can yield intermediates for the synthesis of chiral drugs | [54] |
| (2S,3R) and (2S,3S)-2-chlorophenylglycidol | VCD, OR, ECD | function that can yield intermediates for the synthesis of chiral drugs | [55] |
| (S)-2-(1-(4-chlorophenyl)sulfonyl-2-(2-thienyl)pyrrolidine | VCD, OR, ECD | function that can yield intermediates for the synthesis of chiral drugs | [56] |
| (S)-2-(2-chloro-4-pyridinyl)-1,1,1-trifluoro-2-propanol | VCD, OR | function that can yield intermediates for the synthesis of chiral drugs | [57] |
| (15,25C) Cipralisant (GT-2331) | VCD | H3 antagonist | [58] |
| (S)-3-cyanomethyl-3-hydroxyindole | VCD, ECD | antifungal agent | [59] |
| (S)-desfurane | VCD, OR | antifungal agent | [60] |
| (S)-dihloroeprop | VCD, OR | antiinflammatory | [61] |
| (S)-dioxo-octamethyl | VCD, ECD | antifungal agent | [62] |
| (S)-Etherez | VCD | antifungal agent | [63] |
| (S)-enfurane | VCD, OR | antiinflammatory | [64] |
| (15,2R)-epheprine | VCD, ROA | Head group in Potent GPR40 Full Agonists | [65] |
| (S)-Ethyl-1-hydroxy-2,3-dihydrospiro[cyclopropane-1,1’-indene]-2-carboxylate | VCD, OR | Head group in Potent GPR40 Full Agonists | [66] |
| (S)-etodolac | VCD | antiflammatory | [67] |
| (15,2S,3R)-Ezetimibe | VCD | to treat high cholesterol | [68] |
| (R,R)-Filorexant | VCD | Orexin Receptor Antagonist | [69] |
| (S)-Flecainide | VCD, OR | antarrhythmic | [70] |
| (2R,3R) and (2S,3S)-2-fluoroxy-1-ylalkylglycidol | VCD, OR, ECD | function that can yield intermediates for the synthesis of chiral drugs | [71] |
| (2R,3R) and (2S,3S)-2-fluoroxy-1-ylalkylglycidol | VCD, OR, ECD | function that can yield intermediates for the synthesis of chiral drugs | [72] |
| (2S,3R) and (2S,3S)-4-fluoroxy-1-ylalkylglycidol | VCD, OR, ECD | function that can yield intermediates for the synthesis of chiral drugs | [73] |
| (2R,3R) and (2S,3S)-4-(4-fluoroxy)-1-ylalkylglycidol | VCD, OR, ECD | function that can yield intermediates for the synthesis of chiral drugs | [74] |
| (1R,5S)-Frontalin | VCD | precursor to paroxetine and lomefoxetine | [75] |
| (1R,3S)-Frontalin | VCD | pheromone | [76] |
Table 1. Cont.

| Molecule | Methods Used | Practical Use | References |
|----------|--------------|---------------|------------|
| (R)-Gossypol | VCD | Antineoplastic agent | [67] |
| (R)-4-hydroxywarfarin | VCD | anticoagulant | [68] |
| (R)-6-hydroxywarfarin | ECD | anticoagulant | [68] |
| (R)-7-hydroxywarfarin | ECD | anticoagulant | [68] |
| (R)-8-hydroxywarfarin | ECD | anticoagulant | [68] |
| (S)-Buprofen | VCD | antiinflammatory | [40,70] |
| (7R,8R,10S)-imuloxin A | ECD, OR, VCD | phytotxin | [71] |
| (S)-Iflurane | VCD, OR, ROA | anesthetic | [72,73] |
| (2R,4S)-itraconazole | VCD | antifungal agent | [74] |
| (2R,4S)-ketoconazole | VCD | antifungal agent | [74] |
| (R)-Laropiprant | VCD | prostaglandin D2 receptor 1 antagonist | [40] |
| (R)-malathion | VCD | pesticide | [75] |
| (6S,10bR)-McN 5652-X | VCD | transport of serotonin in brain | [76] |
| (R)-mecrop | VCD | herbicide | [57-59] |
| (2R,3R) and (2S,3S)-3-methoxyphenylglycidol | VCD, OR, ECD | functionality that can yield intermediates for the synthesis of chiral drugs | [52] |
| (S)-miconazole | VCD | antifungal agent | [74] |
| (R)-mirtazapine | VCD | antidepressant | [77] |
| (R)-N-(Pyridin-3-yl)-1-(4-(trifluoromethyl)phenyl)-3,4-dihydriisoquinoline-2(1H)-carboxamide | | TRPM8 antagonists | [78] |
| (S)-Naproxen | VCD | antiinflammatory | [60] |
| (1S,2R)-N-methylephedrine | VCD | antiinflammatory | [62] |
| (1S,2S)-N-methylpseudoephedrine | VCD, ROA | antiinflammatory | [62,63] |
| (1S,2R)-norephedrine | VCD, ROA | antiinflammatory | [62,63] |
| (1S,2S)-norpseudoephedrine | VCD, ROA | antiinflammatory | [62,63] |
| (R,R)-Otamixaban | VCD | fXa inhibitor | [80] |
| (S)-oxadiazol-3-one | VCD | calcium channel blocker | [48] |
| (45S,6R)-Oxysporone | ORD, ECD, VCD | herbicides | [81] |
| paclitaxel | VCD | chemotherapy | [82] |
| (2R,3R) and (2S,3S)-Phenylglycidol | VCD, OR, ECD | functionality for the synthesis of chiral drugs | [52] |
| (3S,4R,8R,10R)-Phyllostixin | ORD, ECD, VCD | herbicides | [81] |
| (S)-Propranolol | VCD | antiarrhythmic | [60] |
| (1S,2R)-pseudopephedrine | VCD, ROA | antiarrhythmic | [62,63] |
| (S,S), (R,S), (S,R) and (R,R)-6-pyrimidin-2-yl-octahyro-pyrrolo[2,3-c] pyridine | VCD | core structure for synthesis of functionalized Sarain A | [83] |
| (1SR,4SR,9SR)-Quinidine | VCD | antiarrhythmic | [60,84] |
| RAC-109 | VCD | antiarrhythmic | | [86] |
| (4aR,8aR)-scytolide | VCD, OR, ECD | herbicides | [81] |
| (15S,2R,3S)-seiricardine A | VCD, OR, ECD | phytoxins | [71] |
| (R,S,R,S,R,S)-Simvastatin | VCD | to lower cholesterol and triglycerides | [40] |
| (S) and (R)-Tetrahydriisoquinolines | VCD, OR | RPM8 Antagonists | [85] |
| (R)-Thalidomide | VCD | teratogen | [86] |
| (2R,3R) and (2S,3S)-2-trifluoromethylyphenylglycidol | VCD, OR, ECD | functionality that can yield intermediates for the synthesis of chiral drugs | [52] |
| (2R,3R) and (2S,3S)-3-trifluoromethylyphenylglycidol | VCD, OR, ECD | functionality that can yield intermediates for the synthesis of chiral drugs | [52] |
| (2R,3R) and (2S,3S)-4-trifluoromethylyphenylglycidol | VCD, OR, ECD | functionality that can yield intermediates for the synthesis of chiral drugs | [52] |
| (R)-1,3,5-triphenyl-2-pyrrol | VCD | anti depressant | [87] |
| Valinomycin | VCD, ROA | transport antibiotic | [88,89] |
| (R)-warfarin | ECD | anticoagulant | [68] |
2.5. Spectral Overlap Analysis

Visual spectral analysis does not provide any quantitative measure of agreement between experimental and predicted spectra and may introduce inadvertent user bias. To provide a quantitative measure of agreement, and eliminate the unintended bias, the digital experimental and predicted spectral data are used to calculate the normalized overlap integral between them. If the normalized overlap integral for signed chiroptical spectral data is 1, then the experimental data of the enantiomer used for experimental measurements are reproduced exactly by the AC used for calculations. On the other hand, if the normalized overlap integral for signed chiroptical spectral data is −1, then, the experimental data of the enantiomer used for experimental measurements would be reproduced exactly by the AC, which is opposite to that used for calculations. The normalized overlap integrals for the absorption and Raman spectra, which are between 0 and 1, do not reflect the AC. Nevertheless, it is important to verify that the predicted absorption or Raman spectrum also reproduces the corresponding experimental spectrum (vide infra). Similarity overlap plots for absorption and CD spectra are shown as insets in Figure 2A,B and Figure 3A,B. The ECD spectral overlap analysis (see inset in Figure 2B) yields a ECD spectral overlap of 0.78 for (−)$_{589}$(6R,7R,8S,10R,2′Z) at a wavelength scale factor of 1.03 and also a overlap of −0.5 at a wavelength scale factor of 0.93. The later value indicates the level of agreement for the opposite enantiomer. This information could not have been obtained from the visual spectral analysis. Even though the overlap for (−)$_{589}$(6R,7R,8S,10R,2′Z) is higher and that for the opposite enantiomer is lower, one should not be overconfident in assigning the AC from ECD spectral overlap alone (vide infra). The VCD spectral overlap analysis (see inset in Figure 3B) yields a overlap of 0.53 at a frequency scale factor of 0.99 for (−)$_{589}$(6R,7R,8S,10R,2′Z) and none with opposite signs. Thus any possible assignment of opposite AC is ruled out from the VCD spectral analysis. Comparison of ORD data also supports (−)$_{589}$(6R,7R,8S,10R,2′Z) assignment [26]. Thus, different chiroptical spectra provide complimentary information that that should be made use of. The spectral overlap analyses discussed in this paragraph have been reported for only a limited number of chiral drugs summarized in Table 1.

Advanced Spectral analysis: When chiroptical spectra are analyzed, a concomitant analysis for accompanying absorption and Raman spectra should also be provided. This is because some of the fundamental quantities involved are common to both of them. However, undertaking separate analyses for them represents an incomplete enquiry. A complete analysis includes comparison of ratio spectra, i.e., ratio of CD to absorption spectra and ratio of ROA to Raman spectra. The former is called dimensionless dissymmetry factor (DF), while the latter is called dimensionless circular intensity difference (CID). The ratio of ECD spectrum to corresponding absorption spectrum is called electronic dissymmetry factor (EDF) spectrum and the ratio of VCD spectrum to corresponding absorption spectrum is called vibrational dissymmetry factor (VDF) spectrum. The EDF and VDF spectra for centratherin are shown in Figures 2C and 3C. The EDF spectral overlap analysis (see inset to Figure 2C) for (−)$_{589}$(6R,7R,8S,10R,2′Z) yields a value of 0.85 and no negative values. Note that, in the previous paragraph, we stated that ECD spectra indicated a possibility for the opposite AC assignment, but EDF spectra now rule out that possibility. This example clearly shows the usefulness of EDF spectra. The VCD spectral overlap analysis (see inset to Figure 3C) for (−)$_{589}$(6R,7R,8S,10R,2′Z) yields a value of 0.62 and no negative values. The overlap values for EDF and VDF are greater than the corresponding values for ECD and VCD. Thus the advanced spectral analysis also suggests the AC of centratherin as (−)$_{589}$(6R,7R,8S,10R,2′Z).

The DF spectral analysis provides more insight than CD spectra alone. Furthermore, as literature studies indicate [69,93], the spectral overlap analysis for DF can be particularly useful when a distinction needs to be made out of several possible diastereomers. In addition, unexpected new information may ensue [94] from DF spectral analyses.

Since DF spectral analyses is a new concept, these analyses have not been yet been generally adopted. However, future investigations are recommended to incorporate the DF analyses, as there is more to gain and nothing to lose in such analyses.
Finally, it should be noted that for molecules with several chiral centers with unknown ACs, a unique solution results when only one diastereomeric structure provides the best match between experimental and predicted chiroptical property. But if multiple diastereomeric structures provide similar matches to the experiment, which is a common occurrence, then a given chiroptical property could not have provided the unique solution for AC. This later situation can be avoided if more than one chiroptical property is simultaneously analyzed for the compound of interest. This is because even if multiple diastereomers may possess the same chiroptical property in a given chiroptical method it is unlikely that they will have the same chiroptical property in another chiroptical method.

3. Conclusions

The pharmaceutical industry has widely adopted the chiroptical spectroscopic methods for establishing the ACs of chiral drugs that they are developing. There are some improvements that can be incorporated in to the methods that are being routinely used. The analysis of DF and CID spectra can improve the reliability of the AC assignments, help discriminate among multiple diastereomers and provide better insight. It is pragmatic, and generally important, to investigate more than one chiroptical property for determining the ACs of chiral molecules.

Acknowledgments: Funding from NSF (CHE-1464874) is gratefully acknowledged. I would like to thank Fernando Martins, Cody Covington, and Mauro de Amorim for their participation in centratherin work [26]. I also thank Chris Welch and Leo Joyce of Merck, Oliver McConnell of Bristol-Myers Squibb and Michael Bartberger of Amgen for providing references to their published articles.

Conflicts of Interest: The author declares no conflict of interest.

References

1. Berova, N.; Polavarapu, P.L.; Nakanishi, K.; Woody, R.W. Comprehensive Chiroptical Spectroscopy: Instrumentation, Methodologies, and Theoretical Simulations; John Wiley & Sons: New York, NY, USA, 2012.
2. Berova, N.; Polavarapu, P.L.; Nakanishi, K.; Woody, R.W. Comprehensive Chiroptical Spectroscopy: Applications in Stereochemical Analysis of Synthetic Compounds, Natural Products, and Biomolecules; John Wiley & Sons: New York, NY, USA, 2012.
3. Eliel, E.L.; Wilen, S.H. Stereochemistry of Organic Compounds; John Wiley: New York, NY, USA, 1994.
4. Covington, C.L.; Polavarapu, P.L. Specific optical rotations and the Horeau effect. Chirality 2015, 28, 181–185. [CrossRef] [PubMed]
5. Harada, N.; Nakanishi, K. Circular Dichroic Spectroscopy: Exciton Coupling in Organic Stereochemistry; University Science Books: Sausalito, CA, USA, 1983; p. 460.
6. Berova, N.; Di Bari, L.; Pescitelli, G. Application of Electronic Circular Dichroism in Configurational and Conformational Analysis of Organic Compounds. Chem. Soc. Rev. 2007, 36, 914–931. [CrossRef] [PubMed]
7. Stephens, P.J.; Devlin, F.J.; Pan, J.-J. The determination of the absolute configurations of chiral molecules using vibrational circular dichroism (VCD) spectroscopy. Chirality 2008, 20, 643–663. [CrossRef] [PubMed]
8. Barron, L.D.; Zhu, F.; Hecht, L.; Tranter, G.E.; Isaacs, N.W. Raman optical activity: An incisive probe of molecular chirality and biomolecular structure. J. Mol. Struct. 2007, 834–836, 7–16. [CrossRef]
9. Nafie, L.A. Vibrational Optical Activity: Principles and Applications; John Wiley and Sons: New York, NY, USA, 2011.
10. Crawford, T.D.; Ruud, K. Coupled-Cluster Calculations of Vibrational Raman Optical Activity Spectra. ChemPhysChem 2011, 12, 3442–3448. [CrossRef] [PubMed]
11. Cheeseman, J.R.; Frisch, M.J.; Devlin, F.J.; Stephens, P.J. Ab initio Calculation of Atomic Axial Tensors and Vibrational Rotational Strengths Using Density Functional Theory. Chem. Phys. Lett. 1996, 252, 211–220. [CrossRef]
12. Autschbach, J. Computing chiroptical properties with first-principles theoretical methods: Background and illustrative examples. Chirality 2009, 21, E116–E152. [CrossRef] [PubMed]
13. Bougas, L.; Sofikitis, D.; Katsoprinakis, G.E.; Spiliotis, A.K.; Tzallas, P.; Loppinet, B.; Rakitzis, T.P. Chiral cavity ring down polarimetry: Chirality and magnetometry measurements using signal reversals. J. Chem. Phys. 2015, 143. [CrossRef] [PubMed]
14. Müller, T.; Wiberg, K.B.; Vaccaro, P.H. Cavity Ring-Down Polarimetry (CRDP): A New Scheme for Probing Circular Birefringence and Circular Dichroism in the Gas Phase. *J. Phys. Chem. A* 2000, 104, 5959–5968. [CrossRef]
15. Sofikitis, D.; Bougas, L.; Katsoprinakis, G.E.; Spiliotis, A.K.; Loppinet, B.; Rakitzis, T.P. Evanscent-wave and ambient chiral sensing by signal-reversing cavity ringdown polarimetry. *Nature* 2014, 514, 76–79. [CrossRef]
16. Dalton: A Molecular Electronic Structure Program. Available online: http://daltonprogram.org (accessed on 10 August 2016).
17. PSI4: An Open-Source Suite of Ab Initio Quantum Chemistry Programs. Available online: http://www.psicode.org/ (accessed on 10 August 2016).
18. Valiev, M.; Bylaska, E.J.; Govind, N.; Kowalski, K.; Straatsma, T.P.; van Dam, H.J.J.; Wang, D.; Nieplocha, J.; Apra, E.; Windus, T.L.; et al. NWChem: A comprehensive and scalable open-source solution for large scale molecular simulations. *Comput. Phys. Commun.* 2010, 181, 1477–1489. [CrossRef]
19. Gaussian09; Gaussian Inc.: Willingford, CT, USA, 2013.
20. ADF: Amsterdam Density Functional Molecular Modeling Suite; Software for Chemistry & Materials (SCM): Amsterdam, The Netherlands, 2014.
21. Shen, J.; Zhu, C.; Reiling, S.; Vaz, R. A novel computational method for comparing vibrational circular dichroism spectra. *Spectrochim. Acta Part A* 2010, 76, 418–422. [CrossRef] [PubMed]
22. Debie, E.; de Gussem, E.; Dukor, R.K.; Herrebout, W.; Nafie, L.A.; Bulthuis, P. A Confidence Level Algorithm for the Determination of Absolute Configuration Using Vibrational Circular Dichroism or Raman Optical Activity. *ChemPhysChem* 2011, 12, 1542–1549. [CrossRef] [PubMed]
23. Covington, C.L.; Polavarapu, P.L. CDSpecTech: Computer Programs for Calculating Similarity Measures for Experimental and Calculated Dissymmetry Factors and Circular Intensity Differentials. Available online: https://sites.google.com/site/cdspectech1/ (accessed on 10 August 2016).
24. Bruhn, T.; Schaumlöffel, A.; Hemberger, Y.; Bringmann, G. SpecDis: Quantifying the Comparison of Calculated and Experimental Electronic Circular Dichroism Spectra. *Chirality* 2013, 25, 243–249. [CrossRef] [PubMed]
25. CompareVOA; BioTools Inc.: Jupiter, FL, USA, 2012.
26. Junior, F.M.S.; Covington, C.L.; de Albuquerque, A.C.F.; Lobo, J.F.R.; Borges, R.M.; de Amorim, M.B.; Polavarapu, P.L. Absolute Configuration of (−)-Centratherin, a Sesquiterpenoid Lactone, Defined by Means of Chiroptical Spectroscopy. *J. Nat. Prod.* 2015, 78, 2617–2623. [CrossRef] [PubMed]
27. Hanwell, M.D.; Curtis, D.E.; Lonie, D.C.; Vandermeersch, T.; Zurek, E.; Hutchison, G.R. Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. *J. Cheminform.* 2012, 4, 1–17. [CrossRef] [PubMed]
28. Spartan: Wavefunction Inc. Available online: https://www.wavefun.com/products/spartan.html (accessed on 10 August 2016).
29. Conflex: High Performance Conformational Analysis. Available online: http://www.conflex.us/ (accessed on 24 May 2010).
30. HyperChem: Hypercube, Inc. Available online: http://www.hyper.com/ (accessed on 10 August 2016).
31. MacroModel 9.6; Schrodinger LLC: New York, NY, USA, 2008.
32. Barron, L.D. *Molecular Light Scattering and Optical Activity*, 2nd ed.; Cambridge University Press: Cambridge, UK, 2004.
33. Polavarapu, P.L. *Vibrational Spectra: Principles and Applications With Emphasis on Optical Activity*; Elsevier: Amsterdam, The Netherlands, 1998.
34. Figadere, B.; Devlin, F.J.; Millar, J.G.; Stephens, P.J. Determination of the absolute configuration of the sex pheromone of the obscure mealybug by vibrational circular dichroism analysis. *Chem. Commun.* 2008, 1106, 1106–1108. [CrossRef] [PubMed]
35. Nieto-Ortega, B.; Casado, J.; Blanch, E.W.; López Navarrete, J.T.; Quesada, A.R.; Ramírez, F.J. Raman Optical Activity Spectra and Conformational Elucidation of Chiral Drugs. The Case of the Antiangiogenic Aeroplysinin-1. *J. Phys. Chem. A* 2011, 115, 2752–2755. [CrossRef] [PubMed]
36. Jiang, N.; Tan, R.X.; Ma, J. Simulations of Solid-State Vibrational Circular Dichroism Spectroscopy of (S)-Alternarlactam by Using Fragmentation Quantum Chemical Calculations. *J. Phys. Chem. B* 2011, 115, 2801–2813. [CrossRef] [PubMed]
37. Ma, Z.; Lin, D.C.H.; Sharma, R.; Liu, J.; Zhu, L.; Li, A.-R.; Kohn, T.; Wang, Y.; Liu, J.; Bartberger, M.D.; et al. Discovery of the imidazole-derived GPR40 agonist AM-3189. *Bioorg. Med. Chem. Lett.* 2016, 26, 15–20. [CrossRef] [PubMed]

38. Pero, J.E.; Rossi, M.A.; Kelly, M.J.; Lehman, H.D.G.F.; Layton, M.E.; Garbaccio, R.M.; O’Brien, J.A.; Magliaro, B.C.; Uslaner, J.M.; Huszar, S.L.; et al. Optimization of Novel Azabenzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI. *ACS Med. Chem. Lett.* 2016, 7, 312–317. [CrossRef] [PubMed]

39. Pivonka, D.E.; Wesolowski, S.S. Vibrational Circular Dichroism (VCD) Chiral Assignment of Atropisomers: Application to g-Aminobutyric Acid (GABA) Modulators Designed as Potential Anxiolytic Drugs. *Appl. Spectrosc.* 2013, 67, 365–371. [CrossRef] [PubMed]

40. Sherer, E.C.; Lee, C.H.; Shpungin, J.; Cuff, J.F.; Da, C.; Ball, R.; Bach, R.; Crespo, A.; Gong, X.; Welch, C.J. A rapid alternative to X-ray crystallography for chiral determination: Case studies of vibrational circular dichroism to advance drug discovery projects. *Bioorg. Med. Chem. Lett.* 2013, 23, 4019–4025. [CrossRef] [PubMed]

41. Geng, Y.; Li, L.; Wu, C.; Chi, Y.; Li, Z.; Xu, W.; Sun, T. Design and Stereochemical Research (DFT, ECD and Crystal Structure) of Novel Bedaquiline Analogs as Potent Antituberculosis Agents. *Molecules* 2016, 21. [CrossRef] [PubMed]

42. Aly, A.; Freedman, T.B.; Cao, X.; Dukor, R.K.; Maryanoff, B.E.; Maryanoff, C.A.; Matthews, J.M.; Shah, R.D.; Nafie, L.A. Determination of the absolute configuration of a key tricyclic component of a novel vasopressin receptor antagonist by use of vibrational circular dichroism. *Chirality* 2002, 14, 215–219. [CrossRef] [PubMed]

43. Chen, J.J.; Qian, W.; Biswas, K.; Yuan, C.; Amegadzie, A.; Liu, Q.; Nixey, T.; Zhu, J.; Ncube, M.; Rzasa, R.M.; et al. Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer’s disease. *Bioorg. Med. Chem. Lett.* 2013, 23, 6447–6454. [CrossRef] [PubMed]

44. Gonzalez-Lopez de Turiso, F.; Sun, D.; Rew, Y.; Bartberger, M.D.; Beck, H.P.; Canon, J.; Chen, A.; Chow, D.; Correll, T.L.; Huang, X.; et al. Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors. *J. Med. Chem.* 2013, 56, 4053–4070. [CrossRef] [PubMed]

45. Carosati, E.; Cruciani, G.; Chiari, A.; Budriesi, R.; Ioan, P.; Spisani, R.; Spinelli, D.; Cosimelli, B.; Fusi, F.; Frosini, M.; et al. Calcium Channel Antagonists Discovered by a Multidisciplinary Approach. *J. Med. Chem.* 2006, 49, 5206–5216. [CrossRef] [PubMed]

46. Shuker, S.; DeVlin, F.J.; Gasparrini, F.; Ciogli, A.; Spinelli, D.; Cosimelli, B. Determination of the Absolute Configuration of a Chiral Oxadiazol-3-one Calcium Channel Blocker, Resolved Using Chiral Chromatography, via Converged Density Functional Theory Calculations of Its Vibrational Circular Dichroism, Electronic Circular Dichroism, and Optical Rotation. *J. Org. Chem.* 2007, 72, 4707–4715. [PubMed]

47. Nishimura, N.; Norman, M.H.; Liu, L.; Yang, K.C.; Ashton, K.S.; Bartberger, M.D.; Chmait, S.; Chen, J.; Cupples, R.; Fotsch, C.; et al. Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 3. Structure–Activity Relationships within the Aryl Carbinol Region of the N-Arylsulfonylamido-N′-aryl)piperazine Series. *J. Med. Chem.* 2014, 57, 3094–3116. [CrossRef] [PubMed]

48. Allen, J.G.; Bourbeau, M.P.; Wohlieter, G.E.; Bartberger, M.D.; Michelsen, K.; Hungate, R.; Gadwood, R.C.; Gaston, R.D.; Evans, B.; Mann, L.W.; et al. Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2—Tumor Protein 53 Protein—Protein Interaction. *J. Med. Chem.* 2009, 52, 7044–7053. [CrossRef] [PubMed]

49. McConnell, O.; He, Y.; Nogle, L.; Sarkahian, A. Application of chiral technology in a pharmaceutical company. Enantiomeric separation and spectroscopic studies of key asymmetric intermediates using a combination of techniques. *Phenylglycidols. Chirality* 2007, 19, 716–730. [CrossRef] [PubMed]
53. Carosati, E.; Budriesi, R.; Ioan, P.; Cruciani, G.; Fusi, F.; Frosini, M.; Saponara, S.; Gasparini, F.; Ciogli, A.; Villani, C.; et al. Stereoselective Behavior of the Functional Diltiazem Analogue 1-(4-Chlorophenyl)sulfonyl)-2-(2-thienyl)pyrrolidinone, a New L-Type Calcium Channel Blocker. *J. Med. Chem.* 2009, 52, 6637–6648. [CrossRef] [PubMed]

54. Pennington, L.D.; Barberger, M.D.; Croghan, M.D.; Andrews, K.L.; Ashton, K.S.; Bourbeau, M.P.; Chen, J.; Chmait, S.; Cupples, R.; Fotsch, C.; et al. Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase–Glucokinase Regulatory Protein (GK–GKRP) Binding: Strategic Use of a N → S (nN → σs,N) Interaction for Conformational Constraint. *J. Med. Chem.* 2015, 58, 9663–9679. [CrossRef] [PubMed]

55. Minick, D.J.; Copley, R.C.B.; Szewczyk, J.R.; Rutkowske, R.D.; Miller, L.A. An investigation of the absolute configuration of the potent histamine H3 receptor antagonist GT-2331 using vibrational circular dichroism. *Chirality* 2007, 19, 731–740. [CrossRef] [PubMed]

56. Monde, K.; Taniguchi, T.; Miura, N.; Nishimura, S.-I.; Harada, N.; Dukor, R.K.; Nafie, L.A. Preparation of cruciferous phytoalexin related metabolites, (−)-dioxibrassinin and (−)-3-cyanomethyl-3-hydroxyoxindole, and determination of their absolute configurations by vibrational circular dichroism (VCD). *Tetrahedron Lett.* 2003, 44, 6017–6020. [CrossRef]

57. He, J.; Wang, F.; Polavarapu, P.L. Absolute configurations of chiral herbicides determined from vibrational circular dichroism. *Chirality* 2005, 17, S1–S8. [CrossRef] [PubMed]

58. He, J.; Polavarapu, P.L. Determination of the absolute configuration of chiral α-aryloxypropanoic acids using vibrational circular dichroism studies: 2-(2-chlorophenoxo) propanoic acid and 2-(3-chlorophenoxo) propanoic acid. Spectrochim. *Acta Part A* 2005, 61, 1327–1334. [CrossRef] [PubMed]

59. He, J.; Polavarapu, P.L. Determination of Intermolecular Hydrogen Bonded Conformers of α-Aryloxypropanoic Acids Using Density Functional Theory Predictions of Vibrational Absorption and Vibrational Circular Dichroism Spectra. *J. Chem. Theory Comput.* 2005, 1, 506–514. [CrossRef] [PubMed]

60. Freedman, T.B.; Long, F.; Citra, M.; Nafie, L.A. Hydrogen-stretching vibrational circular dichroism spectroscopy: Absolute configuration and solution conformation of selected pharmaceutical molecules. *Enantiomer* 1999, 4, 103–119. [PubMed]

61. Zhao, C.; Polavarapu, P.L.; Grosenick, H.; Schurig, V. Vibrational circular dichroism, absolute configuration and predominant conformations of volatile anesthetics: Enflurane. *J. Mol. Struct.* 2000, 550–551, 105–115. [CrossRef]

62. Freedman, T.B.; Ragunathan, N.; Alexander, S. Vibrational circular dichroism in ephedra molecules. Experimental measurement and ab initio calculation. *Faraday Discuss.* 1994, 99, 131–149. [CrossRef] [PubMed]

63. Yu, G.-S.; Che, D.; Freedman, T.B.; Nafie, L.A. Backscattering dual circular polarization raman optical activity in ephedrine molecules. *Tetrahedron Asymmetry* 1993, 4, 511–516. [CrossRef]

64. Wang, Y.; Liu, J.; Dransfield, P.J.; Zhu, L.; Wang, Z.; Du, X.; Jiao, X.; Su, Y.; Li, A.-R.; Brown, S.P.; et al. Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles. *ACS Med. Chem. Lett.* 2013, 4, 551–555. [CrossRef] [PubMed]

65. McConnell, O.; Bach, A.; Balibar, C.; Byrne, N.; Cai, Y.; Carter, G.; Chlenov, M.; Di, L.; Fan, K.; Göljer, I.; et al. Enantiomeric separation and determination of absolute stereochemistry of asymmetric molecules in drug discovery—Building chiral technology toolboxes. *Chirality* 2007, 19, 658–682. [CrossRef] [PubMed]

66. Ashvar, C.S.; Stephens, P.J.; Eggimann, T.; Wieser, H. Vibrational circular dichroism spectroscopy of chiral pheromones: Frontalin (1,5-dimethyl-6,8-dioxabicyclo[3.2.1]octane). *Tetrahedron Asymmetry* 1998, 9, 1107–1110. [CrossRef]

67. Freedman, T.B.; Cao, X.; Oliveira, R.V.; Cass, Q.B.; Nafie, L.A. Determination of the absolute configuration and solution conformation of gossypol by vibrational circular dichroism. *Chirality* 2003, 15, 196–200. [CrossRef] [PubMed]

68. Regalado, E.L.; Sherer, E.C.; Green, M.D.; Henderson, D.W.; Thomas Williamson, R.; Joyce, L.A.; Welch, C.J. Chromatographic Separation and Assignment of Absolute Configuration of Hydroxywarfarin Isomers. *Chirality* 2014, 26, 95–101. [CrossRef] [PubMed]

69. Derewacz, D.K.; McNees, C.R.; Scalmani, G.; Covington, C.L.; Shanmugam, G.; Marnett, L.J.; Polavarapu, P.L.; Bachmann, B.O. Structure and Stereochemical Determination of Hypogeamicins from a Cave-Derived Actinomycete. *J. Nat. Prod.* 2014, 77, 1759–1763. [CrossRef] [PubMed]
70. Izumi, H.; Ogata, A.; Nafie, L.A.; Dukor, R.K. A Revised Conformational Code for the Exhaustive Analysis of Conformers with One-to-One Correspondence between Conformation and Code: Application to the VCD Analysis of (S)-Ibuprofen. *J. Org. Chem.* 2009, 74, 1231–1236. [CrossRef] [PubMed]

71. Santoro, E.; Mazzeo, G.; Petrovic, A.G.; Cimmino, A.; Koshoubu, J.; Evidente, A.; Berova, N.; Superchi, S. Absolute configurations of phytotoxins seiricardine A and inuloxin A obtained by chiroptical studies. *Phytochemistry* 2015, 116, 359–366. [CrossRef] [PubMed]

72. Polavarapu, P.L.; Cholli, A.L.; Vernice, G. Absolute configuration of isoflurane. *J. Am. Chem. Soc.* 1992, 114, 10953–10955. [CrossRef]

73. Polavarapu, P.L. Determination of Molecular Stereochemistry using Optical Rotatory Dispersion, Vibrational Circular Dichroism and Vibrational Raman Optical Activity. In *Chiral Analysis*; Busch, K.W., Busch, M.A., Eds.; Elsevier Science: Oxford, UK, 2011.

74. Dunmire, D.; Freedman, T.B.; Nafie, L.A.; Aeschlimann, C.; Gerber, J.G.; Gal, J. Determination of the absolute configuration and solution conformation of the antifungal agents ketoconazole, itraconazole, and miconazole with vibrational circular dichroism. *Chirality* 2005, 17, S101–S108. [CrossRef] [PubMed]

75. Izumi, H.; Ogata, A.; Nafie, L.A.; Dukor, R.K. Structural determination of molecular stereochemistry using VCD spectroscopy and a conformational code: Absolute configuration and solution conformation of a chiral liquid pesticide, (R)-(+) -malathion. *Chirality* 2009, 21, E172–E180. [CrossRef] [PubMed]

76. Maryanoff, B.E.; McComsey, D.F.; Dukor, R.K.; Nafie, L.A.; Freedman, T.B.; Cao, X.; Day, V.W. Structural studies on Mcn-5652-X, a high-affinity ligand for the serotonin transporter in mammalian brain. *Biorg. Med. Chem.* 2003, 11, 2463–2470. [CrossRef]

77. Freedman, T.B.; Dukor, R.K.; van Hoof, P.J.C.M.; Kellenbach, E.R.; Nafie, L.A. Determination of the Absolute Configuration of (−)-Mirtazapine by Vibrational Circular Dichroism. *Helv. Chim. Acta* 2002, 85, 1160–1165. [CrossRef]

78. Horne, D.B.; Tamayo, N.A.; Barberger, M.D.; Bo, Y.; Clarke, J.; Davis, C.D.; Gore, V.K.; Kaller, M.R.; Lehto, S.G.; Ma, V.V.; et al. Optimization of Potency and Pharmacokinetic Properties of Tetrahydroisoquinoline Transient Receptor Potential Melastatin 8 (TRPM8) Antagonists. *J. Med. Chem.* 2014, 57, 2989–3004. [CrossRef] [PubMed]

79. Thiel, O.R.; Achmatowicz, M.; Bernard, C.; Wheeler, P.; Savarin, C.; Correll, T.L.; Kasparian, A.; Allgeier, A.; Barberger, M.D.; Tan, H.; et al. Development of a Practical Synthesis of a p38 MAP Kinase Inhibitor. *Org. Process Res. Dev.* 2009, 13, 230–241. [CrossRef]

80. Shen, J.; Yang, J.; Heyse, W.; Schweitzer, H.; Nagel, N.; Andert, D.; Zhu, C.; Morrison, V.; Nemeth, G.A.; Chen, T.-M.; et al. Enantiomeric characterization and structure elucidation of Otamixaban. *J. Pharm. Anal.* 2014, 4, 197–204. [CrossRef]

81. Mazzeo, G.; Santoro, E.; Andolfi, A.; Cimmino, A.; Troselj, P.; Petrovic, A.G.; Superchi, S.; Evidente, A.; Berova, N. Absolute Configurations of Fungal and Plant Metabolites by Chiroptical Methods. ORD, ECD, and VCD Studies on Phyllostin, Scytolide, and Oxysporone. *J. Nat. Prod.* 2013, 76, 588–599. [CrossRef] [PubMed]

82. Goljer, I.; Molinari, A.; He, Y.; Nogle, L.; Sun, W.; Campbell, B.; McConnell, O. Unexpected rearrangement of enantiomerically pure 3-aminoquinuclidine as a simple way of preparing diastereomeric octahydropyrrolo[2,3-c]pyridine derivatives. *Chirality* 2009, 21, 681–691. [CrossRef] [PubMed]

83. Sen, A.; Bouchet, A.; Lepère, V.; Le Barbu-Debus, K.; Scuderi, D.; Piuzzi, F.; Zehnacker-Rentien, A. Conformational Analysis of Quinine and Its Pseudo Enantiomer Quinidine: A Combined Jet-Cooled Spectroscopy and Vibrational Circular Dichroism Study. *J. Phys. Chem. A* 2012, 116, 8334–8344. [CrossRef] [PubMed]

84. Polavarapu, P.L.; Bo, Y.; Gore, V.; Ma, V.; Nishimura, N.; Tang, P.; Deng, H.; Klionsky, L.; Lehto, S.G.; Wang, W.; et al. Fused Piperidines as a Novel Class of Potent and Orally Available Transient Receptor Potential Melastatin Type 8 (TRPM8) Antagonists. *J. Med. Chem.* 2012, 55, 1593–1611. [CrossRef] [PubMed]

85. Tamayo, N.A.; Bo, Y.; Gore, V.; Ma, V.; Nishimura, N.; Tang, P.; Deng, H.; Klionsky, L.; Lehto, S.G.; Wang, W.; et al. Fused Piperidines as a Novel Class of Potent and Orally Available Transient Receptor Potential Melastatin Type 8 (TRPM8) Antagonists. *J. Med. Chem.* 2012, 55, 1593–1611. [CrossRef] [PubMed]
87. Vanthuyne, N.; Roussel, C.; Naubron, J.-V.; Jagerovic, N.; Lázaro, P.M.; Alkorta, I.; Elguero, J. Determination of the absolute configuration of 1,3,5-triphenyl-4,5-dihydropyrazole enantiomers by a combination of VCD, ECD measurements, and theoretical calculations. *Tetrahedron Asymmetry* 2011, 22, 1120–1124. [CrossRef]

88. Wang, F.; Zhao, C.; Polavarapu, P.L. A study of the conformations of valinomycin in solution phase. *Biopolymers* 2004, 75, 85–93. [CrossRef] [PubMed]

89. Yamamoto, S.; Straka, M.; Watarai, H.; Bour, P. Formation and structure of the potassium complex of valinomycin in solution studied by Raman optical activity spectroscopy. *Phys. Chem. Chem. Phys.* 2010, 12, 11021–11032. [CrossRef] [PubMed]

90. Julíneka, O.; Setnicka, V.; Rezáčová, A.; Dohnal, J.; Vosátka, V.; Urbanová, M. Product of alaptide synthesis: Determination of the absolute configuration. *J. Pharm. Biomed. Anal.* 2010, 53, 958–961. [CrossRef] [PubMed]

91. Nafie, L.A.; Dukor, R.K. Applications of Vibrational optical activity in the Pharmaceutical Industry. In *Applications of Vibrational Spectroscopy in Pharmaceutical Research and Development*; Pivonka, D.E., Chalmers, J.M., Griffiths, P.R., Eds.; John Wiley: New York, NY, USA, 2007; pp. 129–154.

92. Tsankov, D.; Polyanichko, A.; Wieser, H. Vibrational Circular Dichroism: Ensuring Quality of Pharmaceutical Products. In *Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing*; Gad, S.C., Ed.; John Wiley and Sons: New York, NY, USA, 2011.

93. Junior, F.M.S.; Covington, C.L.; de Amorim, M.B.; Velozo, L.S.M.; Kaplan, M.A.C.; Polavarapu, P.L. Absolute Configuration of a Rare Sesquiterpene: (+)-3-Ishwarone. *J. Nat. Prod.* 2014, 77, 1881–1886. [CrossRef] [PubMed]

94. Covington, C.L.; Polavarapu, P.L. Solvation dependence observed in the electronic dissymmetry factor spectra: How much information are we missing by analyzing the circular dichroism spectra alone? *Phys. Chem. Chem. Phys.* 2016, 18, 13912–13917. [CrossRef] [PubMed]

© 2016 by the author; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).